News
TPST
0.9189
-0.39%
-0.0036
Weekly Report: what happened at TPST last week (0106-0110)?
Weekly Report · 1d ago
Tempest Therapeutics receives ODD from FDA for TPST-1120
TipRanks · 01/06 13:15
Tempest Receives Orphan Drug Designation From The U.S. FDA For Amezalpat To Treat Patients With Hepatocellular Carcinoma
Benzinga · 01/06 13:08
TEMPEST RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR AMEZALPAT TO TREAT PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
Reuters · 01/06 13:00
Weekly Report: what happened at TPST last week (1230-0103)?
Weekly Report · 01/06 11:44
Weekly Report: what happened at TPST last week (1223-1227)?
Weekly Report · 12/30/2024 11:37
Weekly Report: what happened at TPST last week (1216-1220)?
Weekly Report · 12/23/2024 11:44
Tempest Therapeutics’ PPARalpha inhibitor receives FDA orphan designation
TipRanks · 12/16/2024 23:55
Weekly Report: what happened at TPST last week (1209-1213)?
Weekly Report · 12/16/2024 11:46
Weekly Report: what happened at TPST last week (1202-1206)?
Weekly Report · 12/09/2024 11:44
TEMPEST REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/06/2024 21:30
Weekly Report: what happened at TPST last week (1125-1129)?
Weekly Report · 12/02/2024 11:44
Tempest Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
Barchart · 11/26/2024 01:52
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
Barchart · 11/25/2024 15:30
Weekly Report: what happened at TPST last week (1118-1122)?
Weekly Report · 11/25/2024 11:34
Weekly Report: what happened at TPST last week (1111-1115)?
Weekly Report · 11/18/2024 11:31
Tempest Therapeutics Reports Q3 2024 Financial Results
TipRanks · 11/14/2024 04:38
Tempest Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 11/13/2024 17:00
Tempest Therapeutics Price Target Cut to $5.00/Share From $8.00 by Piper Sandler
Dow Jones · 11/13/2024 17:00
Piper Sandler Maintains Overweight on Tempest Therapeutics, Lowers Price Target to $5
Benzinga · 11/13/2024 16:50
More
Webull provides a variety of real-time TPST stock news. You can receive the latest news about Tempest Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.